Thu.Dec 07, 2023

article thumbnail

Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfalls

Fierce Pharma

When it comes to manufacturing cell therapies, it's often said that the "process is the product." But churning out these complex, individualized drugs has routinely tripped up even the industry's l | In recent months, Novartis has faced scrutiny from the FDA over Kymriah production shortfalls, a newly posted letter shows. The company says it's working to address the situation.

article thumbnail

AI’s Role in Transforming Healthcare

MedCity News

Embracing the possibilities that AI unlocks, our commitment to seamlessly integrating AI into healthcare workflows reflects our belief that technology should melt into the background, empowering human caregivers to focus on delivering compassionate patient care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sanofi's quiet Sarclisa chalks up a first-in-class win with eyes on a first-line multiple myeloma nod

Fierce Pharma

In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little. | In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little with Johnson & Johnson.

264
264
article thumbnail

ChatGPT Does a Bad Job of Answering People’s Medication Questions, Study Finds

MedCity News

Researchers recently tested ChatGPT’s ability to answer patient questions about medication, finding that the AI model gave wrong or incomplete answers about 75% of the time. Providers should be wary of the fact that the model does not always give sound medical advice, given many of their patients could be turning to ChatGPT to answer health-related questions.

Medical 131
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

For Merck, Lynparza fails to improve on Keytruda in first-line lung cancer

Fierce Pharma

Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer (NSCLC). | Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer just as its TIGIT program goes up in flames.

263
263
article thumbnail

How Can Health Systems Cut Through the AI Noise? 3 Leaders Answer

MedCity News

During a webinar, three health system leaders discussed strategies they use to ensure successful AI deployment. They agreed that one of the best ways health systems can prime themselves for fruitful AI deployments is beginning with a specific problem to solve — as opposed to having AI startups tell them which problems need to be addressed.

Medicine 122

More Trending

article thumbnail

Why Nurses Crave Time to Teach Other Nurses

MedCity News

During a critical nursing shortage, practicing nurses want to be allowed more time for teaching and mentoring fellow nurse learners, as there are multiple benefits for both sides that could result in improved satisfaction.

Education 122
article thumbnail

Fierce Pharma Asia—WuXi Bio's plunge; Daiichi-Novartis $182M settlement; Merck KGaA's Abbisko deal

Fierce Pharma

WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute. | WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute.

Pharma 243
article thumbnail

Trial finds Lilly’s Olumiant could treat type 1 diabetes

pharmaphorum

Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, potentially opening up a whole new avenue of therapy.

Patients 117
article thumbnail

'The Top Line': Turning down the toxicity of nature’s most powerful antifungal

Fierce Pharma

The antifungal agent Amphotericin B is highly effective against a wide range of deadly fungi and resistance is rare, even after decades of use. | Amphotericin B, an effective antifungal with rare resistance, is associated with significant kidney damage, prompting the search for a potential alternative. This week on "The Top Line," Fierce Biotech Research’s Helen Floersh spoke with Martin Burke, M.D., Ph.D., founder of antifungal startup Sfunga Therapeutics, to discuss the design and pa

130
130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

pharmaphorum

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics which spun out of Pfizer in 2018.

116
116
article thumbnail

Vanda expands commercial presence with $100M deal for US rights to J&J multiple sclerosis drug

Fierce Pharma

Vanda Pharmaceuticals has a new commercial asset under its belt after striking a deal to buy certain rights to Johnson & Johnson’s multiple sclerosis med Ponvory for $100 million. | The multiple sclerosis drug has "potentially broad applications," Vanda's CEO said. J&J launched the med in 2021 and has yet to reveal its sales figures.

Sales 130
article thumbnail

How to Choose the Right Distribution Partner

MedCity News

By understanding the interconnectedness of the healthcare industry, aligning goals and maintaining an open line of communication, distributors and healthcare organizations can cultivate lasting, dependable partnerships, while working together to develop innovative ideas and solutions.

article thumbnail

Lung cancer screening recommended in Scotland, Wales and Northern Ireland

PharmaTimes

The disease is one of the leading causes of cancer deaths in the UK - News - PharmaTimes

Leads 114
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Common drug could facilitate “huge step-change” in managing type 1 diabetes

European Pharmaceutical Review

Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet.  baricitinib… [demonstrated an ability to] preserve the body’s own insulin production and suppress the progression of type 1 diabetes in people who initiated treatment within 100 days of diagnosis” The researchers noted that baricit

article thumbnail

Medtronic drops $738m takeover of wearable insulin pump firm

pharmaphorum

Medtech giant Medtronic has decided not to go ahead with a planned acquisition of EOFlow, a developer of patch-based insulin pumps, saying that there have been “multiple breaches” of their takeover agreement.

110
110
article thumbnail

FDA fast tracks Solid Biosciences’s Duchenne gene therapy

Pharmaceutical Technology

The FDA has granted fast track designation to Solid Biosciences’s gene therapy SGT-003 for the treatment of DMD.

FDA 105
article thumbnail

MedKitDoc Founder Develops Advanced Telemedicine Platform Integrating Medtech for Effective Remote Healthcare

MedCity News

MedKitDoc Founder Dorian Koch shared the journey of the startup, which wants to transform the way patients receive healthcare.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Japan approves BMS’ Abecma for multiple myeloma treatment

Pharmaceutical Technology

Japan has granted approval for the sBLA of Bristol-Myers Squibb (BMS) for Abecma to treat relapsed or refractory multiple myeloma (RRMM).

105
105
article thumbnail

Sanofi says new drugs can add €10bn to sales by 2030

pharmaphorum

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.

Sales 103
article thumbnail

Prevalence of Eight Chronic Health Conditions Reach Unprecedented Levels in US

PharmExec

Arthritis, asthma, cancer, cardiovascular diseases, chronic kidney disease, COPD, depression, and diabetes reach the highest recorded levels since the America’s Health Rankings Annual Report began tracking them in 1990.

98
article thumbnail

‘Innovation-first’ mindset vital for advanced therapies sector future

European Pharmaceutical Review

A report from the Advanced Therapies Treatment Centre (ATTC) Network has highlighted urgent need for rapid change and improvement in the field to maximise patient access to advanced therapies. It was compiled based on expertise gathered at the ATTC Network’s UK Advanced Therapies Adoption Challenge event in October. At the event, attendees discussed barriers and develop solutions to the advanced therapies adoption challenge.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Study reveals reducing oxygen levels for children in ICUs will save lives

PharmaTimes

Around 20,000 children are admitted to ICUs every year in the UK - News - PharmaTimes

80
article thumbnail

Real Chemistry’s CEO on biopharma’s outlook in 2024

PharmaVoice

Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

article thumbnail

Sosei wins South Korean approval for brain injury drug

Pharmaceutical Technology

South Korean regulators approved Sosei’s brain injury drug Pivlaz despite previous negative Phase III results.

59
article thumbnail

Clarivate named as a Representative Vendor in the 2023 Gartner® Market Guide for Intellectual Property Management Software With R&D-Specific Use Cases report

Clarivate

Research and development (R&D) plays a fundamental role in generating the innovation that is essential for maintaining competitive advantage. We are pleased that Clarivate is included in the recently released Gartner report, Market Guide for Intellectual Property Management Software With R&D-specific Use Cases. “This guide offers R&D leaders a sampling of available IP management products that deliver on R&D-related use cases.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Ipsen/Genfit eye June FDA verdict for liver drug elafibranor

pharmaphorum

The FDA has kicked off a priority review of Genfit and Ipsen’s elafibranor as a treatment for rare cholestatic liver disease primary biliary cholangitis (PBC), setting a date of 10th June to deliver a decision.

FDA 59
article thumbnail

Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer

Pharmacy Times

Improvements in PFS were also seen among patients with brain metastases.

article thumbnail

How to Get into Pharmaceutical Sales

Rep-Lite

Getting into pharmaceutical sales and selling pharmaceutical products may require patience and persistence, but for individuals with the right qualifications and a passion for the field, it can be a rewarding and financially lucrative career. In this article, we’ll delve into the intricacies of how to get into pharmaceutical sales and the pivotal role of training.

article thumbnail

Study Results Demonstrate Neurodevelopment Comparable Between CHEU, CHUU at 1 Year

Pharmacy Times

The study authors note that addressing environmental factors, such as IPV and food insecurity, can provide further benefits in neurodevelopment regardless of maternal HIV status.

Food 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A